---

---

treatment   tags : Therapeutics   

save search

---

Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $25.81 0.16% 270K |

Health Technology

| 0.0% | O: -1.26% H: 0.0% C: 0.0%
nulibry authorization treatment for therapeutics

---

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $12.21 0.99% 45K |

| 1.38% | O: -1.72% H: 0.0% C: 0.0%
lx2006 fda candidate granted treatment designation for therapeutics therapy

---

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.87 1.78% 91K |

n/a

| Email alert Add to watchlist
disease treatment for meeting therapeutics

---

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $6.04 3.78% 780K |

| 14.12% | O: 25.49% H: 23.75% C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics

---

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.615 -5.56% 700K |

Health Technology

| -2.29% | O: 0.57% H: 11.65% C: 4.55%
disease control treatment trial therapeutics

---

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
TENX | $3.65 -2.93% 7K |

Health Technology

| -5.13% | O: 7.89% H: 1.95% C: -2.93%
first levosimendan treatment ongoing for therapeutics potential

---

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
LSTA | $2.83 3K |

Manufacturing

| -2.41% | O: 0.34% H: 9.62% C: 3.78%
fda drug granted treatment designation for therapeutics

---

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $69.06 1.25% 270K |

Health Technology

| -14.25% | O: 0.32% H: 0.0% C: -3.52%
treatment trial therapeutics solriamfetol

---

Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
Published: 2024-03-28 (Crawled : 21:00) - globenewswire.com
APLT | $5.205 2.87% 230K |

Health Technology

| Email alert Add to watchlist
fda update treatment pdufa therapeutics

---

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Published: 2024-03-26 (Crawled : 13:00) - globenewswire.com
VIRI | $0.461 -2.12% 120K |

Health Technology

| 0.26% | O: 4.41% H: 8.05% C: -12.31%
patent antiviral international publication treatment therapeutics

---

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
Published: 2024-03-25 (Crawled : 23:00) - biospace.com/
STOK | $12.36 -3.21% 130K |

Health Technology

| 93.81% | O: -0.16% H: 8.11% C: 3.34%
stk-001 first treatment therapeutics potential

---

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
APGE | $52.645 -0.8% 85K |

| -22.45% | O: 0.6% H: 2.5% C: -5.58%
apg808 first disease antibody treatment trial therapeutics

---

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
OTLK | $8.88 3.02% 94K |

Health Technology

| 22.44% | O: 52.98% H: 8.82% C: -19.87%
ons-5010 therapeutics chmp positive treatment

---

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
LSTA | $2.83 3K |

Manufacturing

| -8.41% | O: 0.32% H: 9.68% C: 8.06%
fda rare disease granted treatment designation therapeutics

---

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Published: 2024-03-19 (Crawled : 15:30) - biospace.com/
HOTH | $1.18 -1.67% 47K |

Health Technology

| 4.35% | O: 21.74% H: 19.29% C: -3.57%
disease pre-clinical positive treatment alzheimer's therapeutics ht-alz study

---

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ATOS | $1.615 -5.56% 700K |

Health Technology

| 32.56% | O: 1.55% H: 19.85% C: 18.32%
breast update cancer treatment program therapeutics

---

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
CLPT | $5.7 1.6% 45K |

Health Technology

| -20.65% | O: 0.0% H: 0.99% C: -1.27%
fda license treatment application therapeutics submission

---

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $69.06 1.25% 270K |

Health Technology

| -5.97% | O: 0.84% H: 5.95% C: 5.09%
treatment trial therapeutics solriamfetol

---

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
NTLA | $22.13 -3.45% 660K |

Health Technology

| -19.01% | O: -0.88% H: 0.0% C: -2.42%
ntla-2001 first treatment therapeutics study

---

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
PSTX | $2.08 -14.4% 1.2M |

Health Technology

| -28.74% | O: -0.88% H: 0.0% C: -4.14%
fda drug granted treatment designation therapeutics

---

Gainers vs Losers

54%

46%

Top 10 Gainers

WISA 4 | $7.86 349.14% 120M |

Electronic Technology

TPET | $0.4951 114.24% 29M |

n/a

JAGX | $0.1771 49.07% 540M |

Health Technology

SXTC | $2.03 45.0% 27M |

Health Technology

SPCB | $0.3888 40.87% 27M |

Electronic Technology

DYNT | $0.52 40.39% 20M |

Health Technology

SNGX | $0.54 39.86% 7.3M |

Health Technology

BSGM | $1.53 39.09% 2.6M |

Health Technology

MCBC | $13.74 38.37% 1.6M |

Finance

PALI | $5.51 32.45% 28M |

Manufacturing

---

Your saved searches

---